Delcath Systems (DCTH) Reports Prelim Q3 Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to Delcath Systems (DCTH) Reports Prelim Q3 Results

Delcath Systems Announces Preliminary Third Quarter 2024 Revenue Results

October 17, 2024 8:30 AM EDT

$10 Million Quarterly U.S. Revenue Triggers $25 Million Financing Tranche

QUEENSBURY, N.Y.--(BUSINESS WIRE)-- Delcath Systems, Inc. (Nasdaq: DCTH) (Delcath or the Company), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced preliminary revenue results for the third quarter of 2024, achieving $11.2 million, which included the recording of $10.0 million in U.S. revenue from the commercialization of HEPZATO KIT.

The announcement of the recording of $10.0 million in U.S. quarterly revenue from the commercialization of HEPZATO KIT effectively... More